Clinical-stage oncology biotechnology company discovering and developing antibody-based cancer therapies, including bispecific antibodies, antibody-drug conjugates (ADCs), T-cell engagers, and targeted radiopharmaceuticals
Clinical-stage oncology biotechnology company discovering and developing antibody-based cancer therapies, including bispecific antibodies, antibody-drug conjugates (ADCs), T-cell engagers, and targeted radiopharmaceuticals. Its proprietary OGAP®-Verify platform uses highly sensitive mass-spectrometry-based membrane proteomics and cancer-specific target data to identify and validate tumour-selective drug targets; OGAP®-Splice applies AI and machine learning to discover cancer-specific protein-sp